Neuphoria Therapeutics Inc. (NASDAQ:NEUP) Shares Shorted: Short Interest Down 67.9% in October

by · The Markets Daily

Neuphoria Therapeutics Inc. (NASDAQ:NEUP – Get Free Report) saw a significant decrease in short interest during the month of October. As of October 15th, there was short interest totaling 6,429 shares, a decrease of 67.9% from the September 30th total of 20,022 shares. Based on an average daily trading volume, of 16,447 shares, the short-interest ratio is currently 0.4 days. Approximately 0.1% of the shares of the stock are short sold.

Hedge Funds Weigh In On Neuphoria Therapeutics

Large investors have recently modified their holdings of the stock. Merck & Co. Inc. purchased a new stake in shares of Neuphoria Therapeutics in the second quarter valued at $43,818. AdvisorShares Investments LLC boosted its stake in shares of Neuphoria Therapeutics by 15.8% during the 1st quarter. AdvisorShares Investments LLC now owns 155,367 shares of the company’s stock worth $632,000 after purchasing an additional 21,173 shares during the period. Finally, ADAR1 Capital Management LLC bought a new position in Neuphoria Therapeutics during the 2nd quarter valued at about $131,000. Institutional investors own 15.90% of the company’s stock.

Analysts Set New Price Targets

A number of analysts have issued reports on the company. Wall Street Zen raised Neuphoria Therapeutics to a “hold” rating in a research note on Saturday, July 25th. Weiss Ratings reiterated a “sell (d-)” rating on shares of Neuphoria Therapeutics in a research report on Thursday, August 27th. Two equities research analysts have rated the stock with a Hold rating and one has assigned a Sell rating to the stock. According to data from MarketBeat, Neuphoria Therapeutics currently has a consensus rating of “Reduce” and an average price target of $7.00.

View Our Latest Analysis on Neuphoria Therapeutics

Neuphoria Therapeutics Stock Down 0.3%

NASDAQ NEUP traded down $0.01 during trading hours on Friday, hitting $3.05. 70,249 shares of the company were exchanged, compared to its average volume of 26,605. The stock has a 50-day moving average price of $3.57 and a 200 day moving average price of $4.15. Neuphoria Therapeutics has a 52 week low of $3.03 and a 52 week high of $5.53. The stock has a market cap of $16.50 million, a PE ratio of -0.49 and a beta of 0.75.

Neuphoria Therapeutics Company Profile

(Get Free Report)

See Also